Retatrutide

BPC‑157 (Body Protection Compound‑157) is a stable synthetic pentadecapeptide (15 amino acids) originally derived from a protective peptide found in gastric juice, widely studied for its cytoprotective and regenerative potential.
​
Preclinical research suggests it may support soft‑tissue repair (tendons/ligaments), modulate inflammation, and influence vascular signaling involved in healing.
​
Human evidence remains limited, so it is typically positioned as a research compound rather than an approved medicine.​

Cagrisema is a potent new blend, a combination that integrates two peptides – cagrilintide and semaglutide.

Semaglutide is a GLP-1 receptor agonist; a version of human GLP-1 hormone, modified to resist the degradation by the enzyme dipeptidyl peptidase-4. 

Cagrilintdide, on the other hand, is an amylin analogue. Its role is to mimic the human hormone amylin and is structurally designed to be resistant to enzymatic degradation.

Together, these two peptides profoundly influence chemical structures and induce hormonal changes:

• Leading to the receptor changes within the pancreas and the brain
• Boosting insulin secretion 
• Interacting with the receptors involved in appetite regulation
• Mimicking the action of amylin
• Decreasing glucagon secretion

All in all, this is a sophisticated, more importantly, incredibly potent combination of two peptides whose actions complement each other. Cagrisema combination influences some key hormonal processes and plays a role in metabolic regulation.

Human Chorionic Gonadotropin (HCG) is a peptide hormone primarily produced by the placenta during pregnancy. It plays a vital role in supporting fetal development by stimulating the production of essential hormones such as progesterone, helping maintain a healthy pregnancy.

In research settings, HCG is studied for its potential effects on hormonal regulation, metabolic processes, and physiological responses.

Storage & Handling:
To maintain the stability and integrity of this product, store it in a cool, dry place, away from direct sunlight. Handle with care and follow standard laboratory procedures to ensure accurate and reliable results.

Ipamorelin is a pentapeptide and a synthetic ghrelin mimetic (acting as a ghrelin agonist) with high growth hormone (GH) releasing potency. Since it mimics ghrelin and binds to its receptors (GH secretagogues receptors) in the brain, it stimulates the release of GH in the pituitary gland; which leads to an increase in plasma GH levels, but also increased levels in GA tract, lungs, heart, liver, kidney and pancreas.

What differentiates Ipamorelin from other growth hormone releasing peptides is that it stimulates GH in a way that’s most similar to that of growth hormone-releasing hormone.

References:

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
2. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.